Upadacitinib
This oral JAK1-selective inhibitor is used to treat moderate to severe rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and Crohn's disease in adults who have not responded adequately to other treatments. It works by blocking JAK1 enzymes that transmit inflammatory signals, reducing joint inflammation and skin symptoms. Due to risks of serious infections, blood clots, and cardiovascular events, it requires careful patient selection and monitoring.
الوزن الجزيئي
380,3700 g/mol
LogP
2,70
TPSA
78,30 Ų
قاعدة ليبينسكي للخمسة
ناجح
المجالات العلاجية
تصنيفات الأدوية
آلية العمل
Selective JAK1 inhibitor reducing signaling from cytokines implicated in autoimmune diseases.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Selective JAK1 inhibitor reducing signaling from cytokines implicated in autoimmune diseases.
البنية ثنائية الأبعاد
Cite this structure
Embed this structure
SMILES
CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
InChI
InChI=1S/C17H19F3N6O/c1-2-10-7-25(16(27)24-9-17(18,19)20)8-11(10)13-5-22-14-6-23-15-12(26(13)14)3-4-21-15/h3-6,10-11,21H,2,7-9H2,1H3,(H,24,27)/t10-,11+/m1/s1
Molecular Formula
C17H19F3N6O
HBD / HBA
2 / 6
الروابط القابلة للدوران
3
الذرات الثقيلة
27
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
الأسئلة الشائعة
This oral JAK1-selective inhibitor is used to treat moderate to severe rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and Crohn's disease in adults who have not responded adequately to other treatments. It works by blocking JAK1 enzymes that transmit inflammatory signals, reducing joint inflammation and skin symptoms. Due to risks of serious infections, blood clots, and cardiovascular events, it requires careful patient selection and monitoring.
Selective JAK1 inhibitor reducing signaling from cytokines implicated in autoimmune diseases.
Key pharmacokinetic parameters for Upadacitinib: Half-life: 9-14 hours.
Yes, Upadacitinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
Related Drugs
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3622821. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 58557659. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="upadacitinib"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/upadacitinib/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/upadacitinib/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/upadacitinib/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="upadacitinib"></drugfyi-drug>